These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35912835)

  • 1. Emerging drugs for the treatment of sickle cell disease: a review of phase II/III trials.
    Ross JM; Forté S; Soulières D
    Expert Opin Emerg Drugs; 2022 Jun; 27(2):211-224. PubMed ID: 35912835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sickle cell disease: progress towards combination drug therapy.
    Pace BS; Starlard-Davenport A; Kutlar A
    Br J Haematol; 2021 Jul; 194(2):240-251. PubMed ID: 33471938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the diagnosis and treatment of sickle cell disease.
    Brandow AM; Liem RI
    J Hematol Oncol; 2022 Mar; 15(1):20. PubMed ID: 35241123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voxelotor for the treatment of sickle cell disease.
    Vissa M; Vichinsky E
    Expert Rev Hematol; 2021 Mar; 14(3):253-262. PubMed ID: 33602029
    [No Abstract]   [Full Text] [Related]  

  • 5. Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease.
    Ansari J; Moufarrej YE; Pawlinski R; Gavins FNE
    Expert Rev Hematol; 2018 Jan; 11(1):45-55. PubMed ID: 29207881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging pharmacotherapeutic approaches for the management of sickle cell disease.
    Torres L; Conran N
    Expert Opin Pharmacother; 2019 Feb; 20(2):173-186. PubMed ID: 30499731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging drugs in randomized controlled trials for sickle cell disease: are we on the brink of a new era in research and treatment?
    Matte A; Cappellini MD; Iolascon A; Enrica F; De Franceschi L
    Expert Opin Investig Drugs; 2020 Jan; 29(1):23-31. PubMed ID: 31847604
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review.
    Dick MH; Abdelgadir A; Kulkarni VV; Akram H; Chatterjee A; Pokhrel S; Khan S
    Cureus; 2022 May; 14(5):e24920. PubMed ID: 35706735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug Therapies for the Management of Sickle Cell Disease.
    Rai P; Ataga KI
    F1000Res; 2020; 9():. PubMed ID: 32765834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials.
    Ali MA; Ahmad A; Chaudry H; Aiman W; Aamir S; Anwar MY; Khan A
    Exp Hematol; 2020 Dec; 92():11-18.e1. PubMed ID: 32841705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: Hype or hope?
    Leibovitch JN; Tambe AV; Cimpeanu E; Poplawska M; Jafri F; Dutta D; Lim SH
    Blood Rev; 2022 May; 53():100925. PubMed ID: 34991920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease.
    Han J; Saraf SL; Gordeuk VR
    Pharmacotherapy; 2020 Jun; 40(6):525-534. PubMed ID: 32343424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voxelotor: A Novel Treatment for Sickle Cell Disease.
    Herity LB; Vaughan DM; Rodriguez LR; Lowe DK
    Ann Pharmacother; 2021 Feb; 55(2):240-245. PubMed ID: 32674605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voxelotor for the treatment of sickle cell disease in pediatric patients.
    Brown C; Tonda M; Abboud MR
    Expert Rev Hematol; 2022 Jun; 15(6):485-492. PubMed ID: 35671094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging drugs for sickle cell anemia.
    Singh PC; Ballas SK
    Expert Opin Emerg Drugs; 2015 Mar; 20(1):47-61. PubMed ID: 25431087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic strategies for sickle cell disease: towards a multi-agent approach.
    Telen MJ; Malik P; Vercellotti GM
    Nat Rev Drug Discov; 2019 Feb; 18(2):139-158. PubMed ID: 30514970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease.
    Han J; Saraf SL; Gordeuk VR
    Pharmacotherapy; 2020 Jun; 40(6):535-543. PubMed ID: 32350885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging disease-modifying therapies for sickle cell disease.
    Carden MA; Little J
    Haematologica; 2019 Sep; 104(9):1710-1719. PubMed ID: 31413089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine.
    Migotsky M; Beestrum M; Badawy SM
    Pharmacy (Basel); 2022 Sep; 10(5):. PubMed ID: 36287444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the Treatment of Sickle Cell Disease.
    Kapoor S; Little JA; Pecker LH
    Mayo Clin Proc; 2018 Dec; 93(12):1810-1824. PubMed ID: 30414734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.